中国临床医生
中國臨床醫生
중국림상의생
JOURNAL OF CHINESE PHYSICIAN
2014年
5期
43-44,45
,共3页
李红兵%姚暄%支楠%谢荣荣%袁明霞%杨金奎
李紅兵%姚暄%支楠%謝榮榮%袁明霞%楊金奎
리홍병%요훤%지남%사영영%원명하%양금규
糖肾化浊方%糖尿病肾病%尿微量白蛋白排泄率
糖腎化濁方%糖尿病腎病%尿微量白蛋白排洩率
당신화탁방%당뇨병신병%뇨미량백단백배설솔
Tang Shen Hua Zhuo Recipe%Diabetic Nephropathy%Urine Albumin Excretion Rate
目的观察糖肾化浊方治疗郁期糖尿病肾病的临床疗效。方法100例郁期糖尿病肾病患者随机分为治疗组和对照组,各50例。治疗组口服糖肾化浊方免煎颗粒,每日2次,并联合厄贝沙坦150mg/d;对照组口服厄贝沙坦150mg/d。观察尿微量白蛋白排泄率,同时测定空腹血糖、糖化血红蛋白、血肌酐、尿素氮、血脂等。结果按方案完成98例,治疗组48例,对照组50例。6个月后,治疗组尿微量白蛋白排泄率、总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇均优于对照组(P<0.01)。结论糖肾化浊方能有效改善郁期糖尿病肾病。
目的觀察糖腎化濁方治療鬱期糖尿病腎病的臨床療效。方法100例鬱期糖尿病腎病患者隨機分為治療組和對照組,各50例。治療組口服糖腎化濁方免煎顆粒,每日2次,併聯閤阨貝沙坦150mg/d;對照組口服阨貝沙坦150mg/d。觀察尿微量白蛋白排洩率,同時測定空腹血糖、糖化血紅蛋白、血肌酐、尿素氮、血脂等。結果按方案完成98例,治療組48例,對照組50例。6箇月後,治療組尿微量白蛋白排洩率、總膽固醇、甘油三酯、高密度脂蛋白膽固醇、低密度脂蛋白膽固醇均優于對照組(P<0.01)。結論糖腎化濁方能有效改善鬱期糖尿病腎病。
목적관찰당신화탁방치료욱기당뇨병신병적림상료효。방법100례욱기당뇨병신병환자수궤분위치료조화대조조,각50례。치료조구복당신화탁방면전과립,매일2차,병연합액패사탄150mg/d;대조조구복액패사탄150mg/d。관찰뇨미량백단백배설솔,동시측정공복혈당、당화혈홍단백、혈기항、뇨소담、혈지등。결과안방안완성98례,치료조48례,대조조50례。6개월후,치료조뇨미량백단백배설솔、총담고순、감유삼지、고밀도지단백담고순、저밀도지단백담고순균우우대조조(P<0.01)。결론당신화탁방능유효개선욱기당뇨병신병。
Objective To observe the effects of Tang shen hua zhuo Recipe(TSHZR) in the treatment of patients fromⅣstage of diabetic nephropathy. Method One hundred patients withⅣstage DN were randomly assigned into the control group (n=50)treated by irbesartan alone and the treated group (n=50)treated by TSHZR combined with irbesartan for 6 months. All patients received diabetes fundamental drug. The urine albumin excretion rate was used as the assessment index of therapeutic effect,and fasting blood glucose,HbA1c,serum creatinine,blood urea ni-trogen and lipid profiles,were examined as well. Result According to the protocol complete observation of 98 cases, 48 cases in treatment group and control group of 50 cases. The clinical control rates were significantly differences observed among the two groups. After treatment the urine albumin excretion rate,the levels of triglyceride, total cho-lesterol and low density lipid cholesterol in treatment group all significantly lower than control group (P<0. 01), and the levels high density lipid cholesterol in treatment group significantly higher than control group (P<0. 01). Conclusion The results show that TSHZR can effectively improve Ⅳ stage of diabetic nephropathy, compared with irbesartan has more advantages.